Mental health care has a supply problem that no amount of hiring can fix. Braive, the Norwegian digital therapeutics company, has secured EUR 2.8 million in funding to scale its AI-driven platform that extends evidence-based treatment beyond the therapist's office and into the hours, days, and weeks between sessions. Founded by Hermine Bonde Jahren, the Oslo-based company is positioning itself as infrastructure for a mental health system that is buckling under demand.

The numbers are stark. The World Health Organization estimates that one in eight people globally lives with a mental health disorder. In Norway, wait times for psychological treatment through the public health system regularly exceed several months. In the UK, over 1.8 million people are on NHS waiting lists for mental health services. Across Europe and the United States, the pattern repeats: demand for mental health care is surging while the supply of clinicians grows at a fraction of the rate.

Braive's thesis is that the bottleneck is not just therapist availability but the treatment model itself. Traditional therapy concentrates all clinical contact into a 50-minute session once a week or once a fortnight, leaving patients to manage symptoms, practice skills, and maintain progress on their own between appointments. Braive fills that gap with a platform that delivers personalized, evidence-based therapeutic content between sessions, extending the clinician's reach without requiring additional clinical hours.

The clinical insight behind Braive is well-supported by research. Cognitive behavioral therapy, the most widely validated treatment for depression and anxiety, depends heavily on homework: patients practicing new thought patterns, behavioral experiments, and coping strategies outside the therapy room. Studies consistently show that patients who complete between-session assignments have better outcomes than those who do not.

But in practice, between-session engagement is low. Patients forget what was discussed, lose motivation, or lack the structured guidance needed to practice skills effectively. Paper worksheets get lost. Generic self-help apps lack clinical specificity. And therapists have no visibility into what patients are actually doing between appointments.

Braive addresses each of these problems with a platform that integrates directly into the clinical workflow. Therapists assign specific modules, exercises, and content through the platform. Patients access them on their own schedule. And the clinician gets data on engagement, progress, and symptom tracking that informs the next session. The result is a treatment experience that feels continuous rather than episodic.

Braive's use of AI is careful and clinically grounded. The platform uses machine learning to personalize treatment content based on a patient's diagnosis, progress, and engagement patterns. If a patient is working through a CBT program for social anxiety and struggling with a particular module, the system adapts the content delivery and flags the difficulty for the treating clinician.

This approach deliberately avoids the trap that has ensnared several mental health AI companies: trying to replace the therapist entirely. Autonomous AI therapy chatbots have faced scrutiny from regulators, clinicians, and patients who question whether an algorithm can provide the empathy, nuance, and clinical judgment that define effective psychotherapy. Braive sidesteps this debate by positioning its AI as a tool that enhances the therapist's effectiveness rather than one that makes the therapist obsolete.

Norway's public health system, with its universal coverage and centralized procurement, provides an unusual testing environment for digital health companies. If Braive can demonstrate clinical efficacy and cost savings within the Norwegian system, the evidence becomes transferable to other Nordic countries and eventually to larger European markets with similar single-payer or multi-payer structures.

The Norwegian government has been actively exploring digital health solutions to address mental health capacity constraints. In 2024, Norway's health ministry published a strategy for digital mental health services that explicitly called for platforms that extend treatment beyond traditional clinical settings. Braive's product fits this policy direction precisely, giving the company a potential institutional tailwind that pure consumer apps do not enjoy.

The digital therapeutics sector went through a painful correction in 2023 and 2024. Pear Therapeutics, which had been the poster child for prescription digital therapeutics in the US, filed for bankruptcy. Several other DTx companies struggled to generate revenue despite having FDA clearance. The market learned that regulatory approval does not equal commercial adoption, especially in health systems where reimbursement pathways are slow and clinician buy-in is uncertain.

Braive appears to have internalized these lessons. Rather than pursuing a direct-to-consumer model that requires massive marketing spend, or a prescription DTx model that depends on complex reimbursement negotiations, Braive sells directly to healthcare providers and health systems. The clinician is the customer, the patient is the end user, and the value proposition is straightforward: better patient outcomes per clinical hour invested.

This B2B2C model aligns the incentives. Clinicians want tools that make their practice more effective. Health systems want solutions that reduce wait times and improve throughput. Patients want care that does not stop when they leave the office. Braive delivers on all three.

The round is modest in absolute terms but appropriate for a company that is building clinical evidence and health system partnerships before attempting to scale aggressively. In digital health, premature scaling, signing enterprise contracts before the clinical validation is robust, is the most common cause of death.

Braive's approach, build the evidence, prove the model in a home market with a receptive health system, then expand internationally, mirrors the playbook that worked for companies like Kry (now Livi) in telemedicine and Doktor.se in primary care. The Nordic health systems, with their centralized procurement and data-rich environments, are ideal proving grounds for digital health products that need clinical validation before they can compete in larger, more fragmented markets.

Mental health care is broken in ways that hiring more therapists alone will not fix. The demand is too large, the supply is too constrained, and the treatment model is too concentrated in scarce clinical hours. Braive is not trying to replace the therapist. It is trying to multiply the therapist's impact by filling the space between sessions with structured, personalized, evidence-based care. At EUR 2.8 million, it is an early bet. But the problem it addresses is among the most urgent in global health care.